Showing 1 of 1 PublicationsWhat have we learnt from Vioxx?Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? The BMJ 2007, 334: 120. PMID: 17235089, PMCID: PMC1779871, DOI: 10.1136/bmj.39024.487720.68.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsCardiovascular DiseasesCompensation and RedressCyclooxygenase 2 InhibitorsDrug IndustryHumansInterprofessional RelationsLactonesRisk FactorsScientific MisconductSulfonesTime FactorsUnited KingdomUnited StatesConceptsCardiovascular eventsUK patientsDownload Full List
What have we learnt from Vioxx?Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? The BMJ 2007, 334: 120. PMID: 17235089, PMCID: PMC1779871, DOI: 10.1136/bmj.39024.487720.68.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsCardiovascular DiseasesCompensation and RedressCyclooxygenase 2 InhibitorsDrug IndustryHumansInterprofessional RelationsLactonesRisk FactorsScientific MisconductSulfonesTime FactorsUnited KingdomUnited StatesConceptsCardiovascular eventsUK patients